French biotech firm Hybrigenics said this week that it has incorporated a US-based subsidiary, Hybrigenics Corporation.

To be based in Cambridge, Mass., the subsidiary will focus primarily on Hybrigenics' protein-protein interaction fee-for-service business, and will represent the company for US-based "R&D, regulatory, and business development matters," it said.

Hybrigenics' protein-protein interaction business currently generates more than 30 percent of its total revenues in the US, or roughly €1 million ($1.35 million) per year, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.